First Hurdle Cleared for Neurala’s Psychedelic Drugs

Big news out of the Neurala Biosciences camp today.

The company just announced Phase 1 clinical trial data for its second-generation psychedelic candidates, NBX-100 and NBX-200, which are modified DMT–harmala–based compounds.

The Phase 1 studies were conducted in healthy volunteers and were designed primarily to evaluate safety, tolerability, and pharmacokinetics (how the drug behaves in the body).

According to the company, both candidates were generally well tolerated at the doses tested, with no serious adverse events reported. The data supported predictable exposure levels and dose-dependent effects, allowing Neurala to determine appropriate dosing ranges for future studies.

Based on these results, the company now plans to advance NBX-100 and NBX-200 into further clinical development.

Here’s what CEO Dr. Daniel Perkins had to say …

This study represents an important milestone as the first controlled clinical evaluation of a fully standardised, multi-alkaloid DMT–harmala formulation. From the outset, our goal was not simply to standardize, but to design a composition capable of eliciting a psychedelic experience of optimal intensity to drive clinically meaningful change. The data support this precision formulation approach, with acute effect scores exceeding those reported in prior psilocybin and LSD studies.”

You can read more about Neurala Biosciences here: https://www.neurala.co/science